GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

Rating:
Neutral ANDS

Anadys Pharmaceuticals, Inc. (ANDS) rated Neutral with price target $4 by Wedbush Morgan

Posted on: Thursday,  Feb 25, 2010  1:25 PM ET by Wedbush Morgan

Wedbush Morgan rated Neutral Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on 02/25/2010. Previously Wedbush Morgan rated Buy Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on
04/02/2009., when the stock price was $6.69. Since then, Anadys Pharmaceuticals, Inc. has lost 66.67% as of 10/21/2009's recent price of $2.23.
If you would have followed the previous Wedbush Morgan's recommendation on ANDS, you would have lost 66.66% of your investment in 202 days.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/25/2010 1:25 PM Hold
None
1.91 4.00
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2009 9:25 AM Hold
None
2.23 3.00
4/2/2009 1:25 PM Buy
None
6.69 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy